Sep 28, 2026 · 29 min
Cautious investors find strength in cybersecurity and enterprise tech
Choppy Market Persists; Palo Alto Networks, Ligand Pharma, NetApp Lead
The episode shows how portfolio discipline and selective technical setups matter when broad indexes remain vulnerable and many stocks continue to struggle.
- 1A choppy market makes individual stock performance, support levels, and disciplined loss-cutting more important than index headlines.
- 2Palo Alto Networks and Ligand Pharmaceuticals show distinct paths to leadership through cybersecurity strength and biotech royalty-driven growth.
- 3NetApp’s cup-with-handle breakout highlights improving enterprise technology leadership alongside accelerating earnings performance.
Don't miss
NetApp’s move into the buy zone from a cup-with-handle pattern offers the episode’s clearest example of enterprise technology leadership.
The brief
Rachel Fox and Justin Nielsen open with a broadly weak market, where major indexes remain near highs but many stocks continue to struggle beneath the surface.
Justin Nielsen calls the environment a continuing “chop fest,” arguing that portfolio exposure should follow individual stock performance, support levels, and disciplined loss-cutting.
The discussion moves from BUG, gold, the dollar, Treasury yields, and energy prices to SMH and XLV, weighing fragile technical levels against relative strength.
Palo Alto Networks stands out after a pullback to its 21-day moving average, while Ligand Pharmaceuticals shows biotech strength after crossing a downward trend line.
NetApp provides the clearest breakout case, entering the buy zone from a cup-with-handle pattern as enterprise technology leadership and earnings performance accelerate.
The closing guidance is deliberately cautious: treat portfolio results as market feedback, avoid forcing trades, and wait for stronger conditions before increasing exposure.
What was said on this episode
20 statements · 7 positive · 11 negative · 1 mixed · 1 neutral
Market conditions remain choppy and difficult for investors.
“the chop fest continues”
Listen at 2:05
Choppy markets are especially dangerous for investors.
“those are the most dangerous markets of all”
Listen at 4:17
Investors should cut stocks that trigger stop losses.
“If my stocks are triggering stop losses, I'm cutting them.”
Listen at 5:30
Investors should avoid adding to weak stocks and may reduce positions.
“If they're not working, I'm not adding to them and I might be reducing them.”
Listen at 5:34
The Russell 2000 is in a solid downtrend.
“the Russell 2000, that's in a solid downtrend, not looking great at all.”
Listen at 5:54
Cybersecurity will remain an important market area.
“cybersecurity is going to remain a big thing.”
Listen at 8:16
A stronger dollar can affect gold prices.
“when you have a stronger dollar that is going to sometimes have an effect on gold”
Listen at 9:45
Rising 10-year Treasury yields tend to pressure markets.
“a 10 year treasury yield that has been going up quite a bit. And that's something that does tend to be poor for markets.”
Listen at 9:55
Persistently high oil prices raise transportation and other consumer costs.
“that just means, you know, higher prices for transporting goods, higher prices for all sorts of things”
Listen at 12:08
Tight semiconductor ETF trading is likely to break in either direction.
“when you get tight action like that, you kind of expect it to break one way or the other.”
Listen at 13:02
An aging baby-boomer population supports healthcare demand.
“we've got an aging population, the baby boomers.”
Listen at 14:21
Palo Alto Networks and similar stocks could rise sharply if market pressure eases.
“if that market pressure lifts, you could really see some pops.”
Listen at 19:31
Ligand Pharmaceuticals operates as a royalty aggregator.
“they're what's known as a royalty aggregator”
Listen at 20:36
Ligand funds and advances clinical-stage drug-development trials.
“they help fund and advance a lot of those, you know, multiple stage, clinical stage. trials”
Listen at 20:43
Ligand receives profit shares from successful partnered drug programs.
“all they ask for in return is a piece of the profits should that be something that works.”
Listen at 20:52
Ligand Pharmaceuticals is worth monitoring.
“ligand, something that I think is worth watching”
Listen at 21:44
NetApp’s strong ratings make it worth monitoring.
“it's got some great ratings, so worth keeping an eye on.”
Listen at 25:42
Investors should avoid aggressively trading this market.
“I don't think this is a market where you really want to be pushing it.”
Listen at 26:19
Investors who are not progressing should avoid increasing exposure.
“if you aren't making progress, you want to make sure that you're not diving in.”
Listen at 27:05
Investors should reduce exposure when market feedback shows trades are failing.
“if you're getting feedback from the market that those things aren't working, make sure you heed it. just lighten up a little bit.”
Listen at 27:19
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.